Recently it has been shown that both primary tumors and surrounding microenvironment are mmunosuppressive to the innate immune system thereby preventing effective function in direct and antibody mediated tumor cell killing. Immunesuppression is particularly present in primary CLL where the primary tumor cells have production of TGF-B, IL-10, lL-6, and PDL1 along with expanded T-regulatory cells which antagonize immune surveillance and effective antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phaogocytosis (ADCP). Of interest, immune suppression promoted by CLL tumor cells is mediated in part through constitutive activation of B-cell receptor (BCR) signaling. This project is directed to reverse the immunosuppressive tumor and immune cell function through interventions using novel kinase inhibitors targeting two B-cell receptor (BCR) kinases: delta isoform specific PI3-kinase (CAL-101) and Bruton's tyrosine kinase (BTK) (PCI 32765). We will pursue both preclinical in vitro and in vivo studies of these compounds in the context of CLL and assess their effects on both monocyte/macrophage function (with Project Z) and NK cell function (with Project 3). Given that CAL-101 and PCI 32765 reverse tumor cell immunosuppressive properties and are very active therapeutic agents for CLL, we will pursue how to best integrate these two agents monoclonal antibodies directed at CD20 and potentially other targets through pre-clinical mouse in vivo studies and early phase l/ll human clinical trials where CAL-101 and PCI32765 are given as single agents followed by detailed ex-vivo assessment of innate immune function. In addition, we have discovered that IL-21, a novel common-y chain family of cytokine, lacks properties to promote tolerance induced by regulatory T-cell expansion, activates NK-cells with enhanced anti-CD20 ADCC, promotes direct CLL cell apoptosis, and also directly enhances CD20 mediated apoptosis. We have tested our initial hypotheses of IL-21's ability to enhance innate immune cell function through a phase I study of the anti-CD20 rituximab mAb in combination with IL-21 where durable remissions have been observed in CLL. We will attempt to expand the effectiveness of IL-21 through mechanistic studies with the immunomodulating agent lenalidomide which we have demonstrated to upregulate the IL-21 R on CLL cells, promotes IL-21 production by T-cells, directly enhances NK killing and increases NK-cell ADCC with antibodies directed at B-cell targets. This work builds on the overall hypothesis that combination approaches which 1) enhance innate immune function, 2) diminish tumor cell mediated immune suppression, and 3) induce apoptosis in primary CLL will have significant clinical activity. A clinical trial of IL-21, lenalidomide and anti-CD20 therapy will follow our mechanistic preclinical studies.

Public Health Relevance

This work builds on the overall hypothesis that combination approaches which 1) enhance innate immune function , 2) diminish tumor cell mediated immune suppression, and 3) induce apoptosis in primary CLL will have significant clinical activity. At completion of this project we will have advanced a new paradigm for treating CLL without chemotherapy that incorporates: 1) novel B-cell receptor kinase inhibitors to antagonize tumor-cell mediated immune suppression and/or 2) immune modulating agents which also enhance tumor killing to improve the therapeutic effectiveness of anti-CD20 monoclonal antibody therapy.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Dai, Hong-Sheng; Caligiuri, Michael A (2018) Molecular Basis for the Recognition of Herpes Simplex Virus Type 1 Infection by Human Natural Killer Cells. Front Immunol 9:183
Byrd, John C; Smith, Stephen; Wagner-Johnston, Nina et al. (2018) First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget 9:13023-13035
Chen, Luxi; Youssef, Youssef; Robinson, Cameron et al. (2018) CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. Immunity 49:464-476.e4
Olaverria Salavaggione, Gonzalo N; Duggan, Megan C; Carson, William E (2018) Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma. Melanoma Res 28:390-397
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
Latchana, Nicholas; DiVincenzo, Mallory J; Regan, Kelly et al. (2018) Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. J Surg Oncol 118:501-509
Chan, Wing Keung; Kang, Siwen; Youssef, Youssef et al. (2018) A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma. Cancer Immunol Res 6:776-787
Lai, Xiulan; Stiff, Andrew; Duggan, Megan et al. (2018) Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. Proc Natl Acad Sci U S A 115:5534-5539

Showing the most recent 10 out of 294 publications